Why I might buy Smith & Nephew shares after a 6% price surge

A Q3 update sent the Smith & Nephew plc (LSE: SN) share price flying, but I believe there’s more to come.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buy what you know,” goes the old investing mantra. And I think I know Smith & Nephew (LSE: SN), which makes surgical implants, reasonably well. I’ve worked in that business in the past, and I know how widely used and well regarded are its products — they really are among the best.

I’m currently eyeing up possibilities for my next SIPP investment, and the 6% share price spike at Smith & Nephew on Thursday drew my attention. It’s a response to the latest trading update, which reported a 3% rise in third-quarter underlying revenue.

Chief executive Namal Nawana cited US and Emerging Markets growth as driving the overall improvement, with underlying US revenue up 4% and Emerging Markets revenue surging by 10%.

That sounds like really good news, as uncertain US markets have been contributing to the company’s share price volatility all year.

New markets

The firm also reported “strong growth in Reconstruction, Sports Medicine Joint Repair and Advanced Wound Devices,” which are potentially lucrative markets.

Smith & Nephew does appear to be doing well at refocusing the way it does business, with Nawana adding: “These results were achieved while successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation.”

Smith & Nephew’s dividend yields aren’t great, with forecasts a little above the 2% mark. But they should be well covered by earnings and are progressive — and a sustainable and rising divided can be better than a big yield today.

I want to see how well the new strategy progresses, but Smith & Nephew is definitely on my shortlist.

Growth share dip

I’ve also had my eye on NMC Health (LSE: NMC) for some time, though the share price chart has started to look scarily like some of the growth bubbles we’ve seen in the past few years. And I’ve been fearing it might go pop.

But from a peak of 4,376p in August, the price has shed 20% to drop to 3,508p as I write, so are we looking at an unexpected buying opportunity? 

First-half figures in August were impressive, but actually proved to be pivotal for the share price, which went into a two-month slide. Were investors hoping for even better results? It’s hard to tell, but it’s quite common for growth investors to be expecting spectacular results when all they actually get is seriously good ones — and they’ll often run for the hills when that happens.

Upgraded guidance

But NMC revised its guidance upwards a week ago, and that could well have given fresh life to the share price and we’re seeing it moving upwards again. After a strong first half, the firm now expects a 24% rise in revenue for the full year, and has lifted EBITDA guidance from $465m to $480m.

The shares are currently priced at 25 times forecast 2019 earnings per share, which definitely requires solid growth to justify. But predictions suggest 30% EPS rises this year and next, and we’re looking at an attractive PEG ratio of only 0.8.

I still see NMC as a strong growth candidate, with a likelihood of turning into a big-dividend cash cow in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »